During the last session, Nuvation Bio Inc. (NYSE:NUVB)’s traded shares were 1.58 million. At the end of the trading day, the stock’s price was $2.37, reflecting an intraday gain of 2.60% or $0.06. The 52-week high for the NUVB share is $10.45, that puts it down -340.93 from that peak though still a striking 5.06% gain since the share price plummeted to a 52-week low of $2.25. The company’s market capitalization is $586.31M, and the average intraday trading volume over the past 10 days was 1.28 million shares, and the average trade volume was 1.06 million shares over the past three months.
Nuvation Bio Inc. (NYSE:NUVB) trade information
Nuvation Bio Inc. (NUVB) registered a 2.60% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.60% in intraday trading to $2.37 this Thursday, 08/04/22, hitting a weekly high. The stock’s 5-day price performance is -20.47%, and it has moved by -39.85% in 30 days. Based on these gigs, the overall price performance for the year is -71.38%. The short interest in Nuvation Bio Inc. (NYSE:NUVB) is 9.53 million shares and it means that shorts have 7.12 day(s) to cover.
The consensus price target of analysts on Wall Street is $9.70, which implies an increase of 75.57% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2.50 and $14.00 respectively. As a result, NUVB is trading at a discount of -490.72% off the target high and -5.49% off the low.
Nuvation Bio Inc. (NUVB) estimates and forecasts
Statistics show that Nuvation Bio Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Nuvation Bio Inc. (NUVB) shares have gone down -60.10% during the last six months, with a year-to-date growth rate less than the industry average at -18.18% against 1.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -44.40% this quarter and then drop -27.30% in the quarter after that.
While earnings are projected to return -48.60% in 2022.
Nuvation Bio Inc. is due to release its next quarterly earnings between March 09 and March 14. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Nuvation Bio Inc. (NYSE:NUVB)’s Major holders
Nuvation Bio Inc. insiders own 27.07% of total outstanding shares while institutional holders control 77.03%, with the float percentage being 105.61%. FMR, LLC is the largest shareholder of the company, while 169 institutions own stock in it. As of Mar 30, 2022, the company held over 31.6 million shares (or 14.49% of all shares), a total value of $166.21 million in shares.
The next largest institutional holding, with 22.96 million shares, is of Omega Fund Management, Llc’s that is approximately 10.52% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $120.76 million.
Also, the Mutual Funds coming in first place with the largest holdings of Nuvation Bio Inc. (NUVB) shares are Fidelity Contrafund Inc and Fidelity Growth Company Fund. Data provided on May 30, 2022 indicates that Fidelity Contrafund Inc owns about 10.51 million shares. This amounts to just over 4.82 percent of the company’s overall shares, with a $37.1 million market value. The same data shows that the other fund manager holds slightly less at 4.46 million, or about 2.04% of the stock, which is worth about $15.74 million.